Rosistark (Rozistark) tabs 20mg #70

Instruction for Rosistark

Reed more and buy Rosistark on this page

Release form and composition of the drug

Rosistark is a medicine that comes in tablet form. The tablet has a film shell, which helps the drug to enter the necessary parts of the digestive system without changing the pharmacological properties. The drug has a yellowish tint, round shape, neutral odor. The drug is available in ten milligrams in an amount of twenty-eight pieces and twenty milligrams in an amount of twenty-eight tablets. The medicine is packed in a cardboard box along with instructions for the use of Rosistark 1 mg. Description of the constituent components: the main active ingredient of the drug is Rosuvastatin. Its dose is ten or twenty milligrams. The rest of the components are auxiliary elements and form the basis of the tablet and shell. One of the constituent components of Rosistark is lactose. The price of Rosistark depends on the number of milligrams of the active ingredient. The medicine has no analogues.

Pharmacological properties

The molecular formula consists of twenty-two carbon molecules, twenty-eight hydrogen molecules, one fluorine molecule, three nitrogen molecules, six oxygen molecules, and one sulfur molecule. The active ingredient is the active ingredient, it lowers the level of fats in the blood and surrounding human tissues. The elements of the tablets lower lipoproteins of different densities. The drug is designed to lower the level of lipids and fat-like substances in the human body. The implementation of the medicinal substance in medicine began in 2003. It was first developed in Japan by large pharmaceutical companies. In the course of scientific trials, the greatest study of statins has been proven. More than one hundred seventy thousand sick people were taken in the experiments. During the treatment, laboratory tests and ultrasound examinations of intravascular diagnostics were carried out. A decrease in the incidence of heart attacks and strokes was established, due to which the mortality rate of the population decreased. The drug is widely used to combat atherosclerosis. The active ingredient reduces the growth of atherosclerotic plaques inside the vessels, improves the condition of the walls of the arteries and reduces their permeability. The drug selectively inhibits reductase by conversion to mevalonic acid. The resulting product is the direct precursor of cholesterol. Then there is the capture and processing of low density fats. During the synthesis of liver lipoproteins, blood cholesterol decreases. As a result, the size of vascular plaques decreases in atherosclerotic pathology. Blood tests were monitored in patients during therapy. In the blood, a decrease in protein, which is responsible for the inflammatory process in the body, was noted, the level of cholesterol, and cholesterol and low density lipoproteins decreased. Rosistark has good efficacy. Delivery of the active substance in the optimal volume occurs seven days after the start of treatment. In two weeks, the active substance is accumulated in the body and accounts for ninety percent of the therapeutic effect. The maximum therapeutic effect occurs in one calendar month from the beginning of the first pill intake.
One hundred percent of the effectiveness occurs if the patient did not miss pills and took medication daily for two weeks. The main component has a beneficial effect on the state of the body in males and females. The drug does not alter the pharmacological properties of different racial groups and does not depend on age and endocrine diseases. Patients who received the daily daily dose of the drug noted a decrease in cholesterol to the normative level. In patients with a high blood fat content, which occurred as a result of hereditary pathology from parents, a decrease in cholesterol was noted only by twenty percent. And the optimal therapeutic effect occurs twenty-eight days after the start of the first pill intake. In patients with concomitant endocrine diseases, dosage adjustment is not required. After ingestion, the tablet undergoes a metabolic process in the digestive system. Delivery and the rate of saturation of the liquid part of the blood occurs five hours after ingestion. The maximum bioavailability of the active substance is twenty percent of the prescribed dose. Medicines undergo a metabolic process in the liver with the formation of metabolic products. Hepatic metabolism is the main site for the synthesis of fats and low density lipoproteins. The total volume of distribution of the main component is one hundred and thirty-four liters. The active substance enters into a bond with proteins. The main protein for communication is albumin. The active ingredient is slightly associated with albumin, thereby characterizing a positive therapeutic effect. It has been proven that the greater the drug effect, the lower the drug enters into a protein bond. After the protein bond, the active component turns into a protein-bound form, and the final metabolites remain unchanged for five percent of the dose taken. The process of elimination from the human body occurs through the digestive and renal systems. About ninety percent is excreted through the gastrointestinal tract, and the remainder through the urinary system. The withdrawal period does not change and does not depend on the dose. If the dosage is adjusted during therapy, the elimination process remains unchanged. The concentration and duration of blood saturation is fifty liters per hour. In patients with renal pathology, therapy with an active substance is allowed, but during treatment, the patient must also monitor blood tests, ultrasound of the kidneys and monitor urine tests. In patients with pathology of the hepatic system, the pharmacological properties of the drug do not change. Metabolism and excretion processes correspond to those in healthy people. Patients with severe pathology of the hepatic system tolerate the drug worse, the elimination process slows down by half. In this category of patients, blood control, biochemical examination, hemostasis and ultrasound of internal organs are performed.

Indications for use

Rosistark is indicated for the treatment of primary elevated blood lipids and lipoproteins. The drug is prescribed for high blood lipids caused by poor diet. It is also caused by a hereditary or polygenic mutation. The drug is indicated for therapy for mutations in the low-density lipoprotein gene, which leads to the development of pathology of the heart and blood vessels. Also, the drug is prescribed as a combination treatment, which includes diet, exercise and weight loss. Tablets are prescribed for high blood fat, which is homozygous for hereditary mutations. Rosistark is indicated for the prevention and reduction of the likelihood of complications in the heart and blood vessels, to eliminate the risk of stroke and heart attack. Indications include high blood cholesterol and vascular disease, high blood pressure, and a family history of ischemia. Tablets are indicated for the implementation of preventive measures for heart and vascular disease in patients of retirement age, with an increase in inflammatory protein. The drug is indicated in patients with high blood fats, when other drugs and diet have been ineffective. The medicine is prescribed for men and women of different ages. Rosistark 1mg is indicated in the presence of atherosclerosis to prevent further proliferation of atherosclerotic plaques.

Contraindications

Rosistark is contraindicated for treatment in patients with liver pathology, especially disease in the exacerbation phase, and changes in blood tests of hepatic markers. The drug is contraindicated for use in patients with severe renal pathology, with neuromuscular pathology, while taking cyclosporine. It is not recommended for use in patients with muscle complications after surgical treatment, in women who are planning pregnancy, during pregnancy, during breastfeeding and in patients under eighteen years of age. It is unacceptable to use tablets in patients with individual lactose intolerance and with congenital pathology of the absorption of nutrients in the digestive tract. Reception is contraindicated in patients with increased sensitization to the active substance or other component from the composition of the tablets. It is carefully prescribed in patients with thyroid diseases, in the presence of hereditary muscle pathology, while taking other drugs related to reductase inhibitors. It is not recommended to carry out therapy in patients with alcohol abuse and in patients over seventy years of age. The medicine is carefully prescribed in patients with metabolic pathologies, endocrine disorders or water balance disorders. Carefully prescribe Rosistark in patients with epileptic seizures and while taking fibrates.

Instructions for use of Rosistark

The drug Rosistark is taken orally. The drug is taken with or without food. Food does not affect the pharmacological properties, therefore, the intake of tablets does not depend on food. The tablet is taken whole, together with water in a volume of two hundred milliliters. It is advisable not to grind the tablet, since it has a prolonged effect and the release of the active substance occurs gradually along the path of the digestive system. Before starting treatment, the patient undergoes diet therapy using foods that are low in fat and plant foods. The amount of fat per day should not exceed seven percent of the daily food intake. The dosage of the medicine is set individually and depends on the signs of the disease. Before treatment, the patient's blood tests are monitored to exclude symptoms of similar diseases. The initial dosage is five milligrams daily, once a day. After that, the analyzes are monitored, and the doctor decides on the dose adjustment. If the patient missed taking the pill, then he needs to continue taking it according to the prescribed treatment regimen. It is not recommended to take a double dose of the medicine. In some patients, the starting dosage may be ten milligrams per day. The dosage is set based on the blood fat content of each patient, the risk of developing cardiac pathology and the risk of unwanted effects are taken into account. The duration of therapy is twenty-eight days, after which the dose is adjusted again. The duration of the appointment is one calendar month. If the drug is prescribed at the maximum dosage, then the patient's blood counts are carefully monitored. It is undesirable to prescribe the maximum dose if the patient is undergoing treatment for the first time and has not consulted a doctor before. After the first month of treatment, blood fats are monitored and the dose is adjusted. The dosage is also adjusted when other drugs are used together, which increase the pharmacological properties of the active substance. If the pharmacological properties are doubled, then the initial dose of the drug should not exceed five milligrams per day. The dosage is similarly adjusted in patients with the maximum dose. Patients of retirement age do not need dose adjustment. In persons with mild renal pathology, the dose is not adjusted. And in patients with severe kidney disease, the drug is not prescribed, due to the increased risk of developing an unwanted reaction. The drug is not prescribed in persons with liver pathology during an exacerbation.
In patients from Mongolia, pharmacological properties may change. If ten or twenty milligrams of medicine is prescribed for the European race, then for the Mongoloid race, the medicine is prescribed at a dosage of five milligrams per day. It is not recommended to use the maximum dosage of forty milligrams in the Mongoloid race. In persons with neuromuscular diseases that lead to gradual muscle atrophy, the maximum dosage is ten or twenty milligrams of the active ingredient. The starting dosage is five milligrams. It is contraindicated to use forty milligrams as the maximum dosage in this category of patients, due to the high risk of complications. The drug is not prescribed in patients under eighteen years of age, due to the lack of data on use in children. The drug is not addictive and does not accumulate in the body, so it can be reused for treatment.

Side effects

Rosistark's reviews show that the active substance has a side effect on the body in one percent of patients. Rosistark Causes changes in the work of some organs and systems. An undesirable effect on the central nervous system manifests itself in the form of headache, dizziness, neurological disorders, and memory loss. An undesirable effect on the work of the blood is manifested in the form of a decrease in the level of platelets in the blood, changes in the level of proteins. Side effects on the gastrointestinal tract are manifested in the form of constipation, nausea, painful sensations in the epigastric region, inflammatory processes of the pancreas, and indigestion. A side effect on the hepatic system is manifested in the form of an increase in hepatic markers. The effect on the endocrine system is manifested in the form of an increase in blood sugar, changes in the functioning of the thyroid gland, and the development of diabetes mellitus. The effect on muscles is manifested in the form of soreness in the muscles, inflammatory processes of the muscular system, the development of neuromuscular pathology. In most cases, an adverse reaction to the muscular system goes away without any symptoms. The adverse reaction is temporary and goes away on its own after you stop taking the pills. A side effect on the renal system manifests itself in the form of the appearance of proteins in the urine, which proceeds without symptoms and does not change the general well-being. It occurs in three percent of patients. The effect on the skin is manifested in the form of an allergic reaction, itching and burning. In some cases, Quincke's edema can be found. A side effect on the genitals is soreness of the mammary glands, decreased libido. An undesirable effect on laboratory parameters is manifested in the form of an increase in bilirubin in the blood, changes in the level of glucose in the blood, the appearance of protein in the urine, and a decrease in the activity of the thyroid hormone. One percent of patients have malaise, edema of the lower extremities, impaired quality sleep and depression. If tablets are used for long-term therapy, then in rare cases, pathology of the respiratory system develops. At the first signs of the onset of symptoms, adverse reactions should be reported to the attending physician. The doctor will conduct an additional examination and prescribe symptomatic therapy. In the event of a severe adverse reaction, the patient will be prescribed alternative therapy.

Overdose

Rosistark can cause an overdose if the therapy regimen is violated in patients. The medicine is prescribed at a minimum initial dosage and is adjusted during therapy. If an overdose develops, then the main symptoms will be dizziness, malaise, nausea, indigestion, changes in laboratory parameters. After the patient has discovered an overdose, he needs to inform the doctor about it. The doctor, on the basis of tests and general examination, confirmed the diagnosis. After that, the patient will receive symptomatic therapy until complete recovery. After recovery, the doctor will re-evaluate the condition and decide whether to cancel or continue treatment with pills. Rosistark 1 does not undergo hemodialysis and does not have an antidote.

Drug interactions

Rosistark can be used for combined treatment. However, it is unacceptable to use drugs Rosistark 1 mg together with inhibitors of transport proteins, due to the development of altered pharmacological properties. The active ingredient increases the concentration in the blood and increases the risk of developing neuromuscular pathology. The combination of tablets with Cyclosporin leads to a sevenfold increase in the degree of blood saturation, increases the concentration and pharmacological effect. Because of this, the patient may develop an overdose. Combination with drugs that contain vitamin K change the hematological properties of the blood. Also, the combination with anticoagulants changes some indicators of hemostasis. If, nevertheless, the combination is inevitable, then against the background of therapy, it is necessary to monitor hemostasis indicators. The combination of tablets with Ezetimibe does not lead to a change in the pharmacological properties of drugs. The combination of drugs with a similar effect leads to a twofold increase in the maximum concentration. But it does not have a therapeutic significant change on the work of the body. Fibrates lead to the development of neuromuscular pathology. For patients with HIV infection, while taking anti-infectious drugs, tablets increase the maximum concentration of the active substance. Therefore, co-administration with the infection is not recommended. Combined tablets with antacids leads to a decrease in the concentration of the active substance in the blood by fifty percent. Medicines that contain magnesium likewise reduce blood saturation by fifty percent. Combination with Erythromycin increases the maximum concentration of the active substance by thirty percent. Due to the increase in concentration, the peristalsis and motility of the digestive system increase, the work of the gastrointestinal tract changes. Hormonal contraceptives combined with pills result in a twenty-five percent increase in concentration and bioavailability. Such an increase in the active substance can change the pharmacological properties of contraceptives. Food does not affect the bioavailability and absorption of the drug in the digestive system.

Special instructions

Medicines Rosistark should not be used in women who are planning a pregnancy. The active substance is slightly accumulated in the body and is excreted within one calendar month. If a woman is planning to have a baby, then she needs to plan two months after the therapy. A woman needs to undergo pregravid training. During treatment, it is necessary to use reliable methods of contraception. Since hormonal contraceptives affect the pharmacological properties of the active substance, the barrier method is the best choice for contraception. It is unacceptable for women to undergo treatment during pregnancy. The active ingredient easily penetrates the hematoplacental barrier and affects the distribution of fat in the fetus. The drug passes into breast milk, therefore, it is not recommended to use the drug during lactation in women. If a woman needs to continue treatment, then the question of stopping breastfeeding is decided. You can buy Rosistark in an online pharmacy with a doctor's prescription. You can buy Rosistark 1 mg throughout Russia. The drug does not alter memory, does not affect the psycho-motor reaction, does not alter the clarity of vision. Driving during therapy is permitted. It is worth paying attention to the fact that the drug causes a side reaction in the form of dizziness. It is allowed to engage in activities that require increased attention, but if symptoms of an adverse reaction appear, inform a relative or colleague about this about providing first aid. The drug can alter blood glucose levels, which can cause the patient to develop diabetes. For patients with a blood sugar content of 5 millimoles per liter, the use of tablets provokes the development of diabetes mellitus. Since the tablets contain lactose, it is not recommended to use it for treatment in patients with lactose deficiency and with a disease that develops in the small intestine and is accompanied by impaired absorption of nutrients and vitamins. Medical observations have shown that the drug increases pharmacological properties in patients of the Mongolian, Chinese and Japanese races. In representatives of the European race, the pharmacological properties do not change. In patients with a repeated increase in blood cholesterol levels due to the development of thyroid pathology or kidney disease, the thyroid gland and kidneys are first treated, after which the drug is prescribed. It is not recommended to prescribe treatment in persons with acute pathology of concomitant diseases, they can provoke the risk of developing a neuromuscular disorder. Recurrent renal failure may also develop. During treatment, each patient needs to be informed about the symptoms of muscle complications. In case of sudden onset of muscle pain, muscle weakness and march, spastic pain, fever and general malaise, you must immediately inform your doctor. In such patients, changes in the content of creatine kinase in the blood develop. With an increase in creatine kinase, pill therapy is canceled if the indicator exceeds the norm by five times. After discontinuation of treatment, the patient is monitored for analysis. The presence of albumin in the urine appears if the drug is taken at a maximum dosage of forty milligrams. Proteinuria is temporary and indicates the development of the pathology of the renal system. The appearance of protein in the urine during treatment occurs in two percent of patients. In such patients, during therapy, urine is monitored once every seven days. If urine protein increases, consideration should be given to replacing therapy. The development of a syndrome characterized by the destruction of muscle tissue and an increase in blood creatine kinase is extremely rare and the dosage of the drug does not affect the development of pathology.

Terms and conditions of storage

Rosistark medicinal product must be stored under optimal conditions. Rosistark storage temperature should not exceed twenty-five degrees and not drop below two degrees. Store at a relative humidity of seventy percent, and out of sunlight. Store away from children and heating devices. Storage tablets can be placed in the refrigerator, but not frozen. The shelf life of the medicine is thirty-six months. After the expiration of the shelf life, the medicine must be disposed of. After thirty-six months, the drug changes its pharmacological properties and becomes therapeutic ineffective.

Terms of sell

You don't need a prescription to buy Rosistark.